Who are Hydroxychloroquine combined with Azithromycin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Hydroxychloroquine in combination of Azithromycin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hydroxychloroquine-combined-with-azithromycin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Hydroxychloroquine combined with Azithromycin — Competitive Intelligence Brief

Hydroxychloroquine combined with Azithromycin (Hydroxychloroquine combined with Azithromycin) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial + Macrolide antibiotic combination. Area: Infectious Disease / Immunology.

phase 3 Antimalarial + Macrolide antibiotic combination Infectious Disease / Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Hydroxychloroquine combined with Azithromycin (Hydroxychloroquine combined with Azithromycin) — Ministry of Health, Turkey. Hydroxychloroquine inhibits endosomal acidification and toll-like receptor signaling while azithromycin provides macrolide antibiotic activity and immunomodulatory effects, together intended to reduce viral replication and inflammatory response.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Hydroxychloroquine combined with Azithromycin TARGET	Hydroxychloroquine combined with Azithromycin	Ministry of Health, Turkey	phase 3	Antimalarial + Macrolide antibiotic combination
Hydroxychloroquine in combination of Azithromycin	Hydroxychloroquine in combination of Azithromycin	Sheba Medical Center	phase 3	Antimalarial + Macrolide antibiotic combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial + Macrolide antibiotic combination class)

Ministry of Health, Turkey · 1 drug in this class
Sheba Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hydroxychloroquine combined with Azithromycin — Competitive Intelligence Brief. https://druglandscape.com/ci/hydroxychloroquine-combined-with-azithromycin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab